Healthcare Services

Penile Cancer Market Anticipated to Record Steady Gains, Advancing to $37.41 Billion by 2030

February 27, 2026April 15, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the penile cancer market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Penile Cancer Market?

The penile cancer market size has experienced robust growth in recent years. It is projected to increase from $25.86 billion in 2025 to $27.8 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.5%. Historically, this growth can be attributed to factors such as limited awareness and screening, delayed diagnosis, a reliance on conventional surgery and chemotherapy, insufficient specialized treatment centers, and fragmented patient data.

The market for penile cancer treatments is projected to experience substantial expansion in the coming years, anticipated to reach a valuation of $37.41 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.7%. This projected growth is driven by factors such as the increasing uptake of immunotherapy and biological therapies, a growing reliance on personalized medicine strategies, the broadening scope of early detection initiatives, the rise of telemedicine and remote patient oversight, and heightened investment in research and public awareness campaigns concerning penile cancer. Key trends expected during this period involve the greater application of AI in early diagnosis and risk evaluation, the expanding embrace of genomics-based targeted treatments, the merging of cloud computing and big data for comprehensive patient care, the deployment of IoT-enabled devices to track treatment efficacy, and the incorporation of smart manufacturing techniques in the production of biological therapies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12143&type=smp

What Drivers Are Supporting Technological Adoption In The Penile Cancer Market?

The projected growth of the penile cancer market is expected to be propelled by the rising incidence of penile cancer, a condition characterized by the development of malignant cells in the penis tissues. An increase in its occurrence is likely to stimulate demand for diagnostic, surgical, and supportive care services, thereby impacting the penile cancer market. For instance, reports from the American Cancer Society Inc., a US-based voluntary health organization, indicated in January 2023 an anticipation of about 2,050 new cases of penile cancer and 470 related deaths by 2023. Therefore, the increasing incidence of penile cancer serves as a significant driver for the market’s expansion. The expansion of the penile cancer market is anticipated to be driven by the increasing size of the geriatric population, which refers to elderly or older adults. Penile cancer primarily affects older men, with its incidence increasing with age, and it is commonly treated with surgery, radiation therapy, and targeted therapy. An expanding geriatric population also elevates the chances of penile infection. For example, the World Health Organization, a Switzerland-based specialized agency of the United Nations, reported in February 2025 that the global population aged 60 and older is projected to rise from 1.1 billion in 2023 to 1.4 billion by 2030. Consequently, the rise in the geriatric population is a key factor fueling the growth of the penile cancer market.

Which Segments Are Contributing To The Growth Of The Penile Cancer Market?

The penile cancer market covered in this report is segmented –

1) By Type: Squamous Cell Cancer Of Penis, Aden Carcinoma Of Penis, Melanoma Of The Penis, Basal Cell Cancer Of Penis, Sarcoma Of Penis

2) By Type Of Therapy: Radiation Therapy, Chemotherapy, Biological Therapy, Surgery

3) By Diagnostic Test: Biopsy, Ultrasound, Imaging Tests

4) By Application: Hospital, Clinics, Other Applications

Subsegments:

1) By Squamous Cell Cancer Of Penis: Invasive Squamous Cell Carcinoma, Non-Invasive Squamous Cell Carcinoma

2) By Adenocarcinoma Of Penis: Penile Adenocarcinoma, Mucinous Adenocarcinoma, Non-Mucinous Adenocarcinoma

3) By Melanoma Of The Penis: Superficial Spreading Melanoma, Nodular Melanoma, Acral Lentiginous Melanoma

4) By Basal Cell Cancer Of Penis: Nodular Basal Cell Carcinoma, Superficial Basal Cell Carcinoma, Morpheaform Basal Cell Carcinoma

5) By Sarcoma Of Penis: Kaposi’s Sarcoma, Rhabdomyosarcoma

Which Trends Are Influencing The Development Of The Penile Cancer Market?

Leading companies in the penile cancer market are concentrating on inventive solutions, such as advanced cancer trials, to address outstanding medical needs and elevate treatment success rates. Advanced cancer trials involve testing new treatments, therapies, or medications on patients with late-stage cancer to determine their safety and effectiveness. For example, in May 2023, the ECOG-ACRIN Cancer Research Group, a US-based scientific organization, enrolled 100 patients in the InPACT (International Penile Advanced Cancer Trial), which offers a beacon of hope for men with advanced cancer of the penis. The International Penile Advanced Cancer Trial (InPACT) is a research undertaking focused on studying advanced stages of penile cancer, aiming to improve treatment outcomes and quality of life for affected individuals. It evaluates novel therapies, surgical methods, and interventions for patients with advanced penile cancer, pursuing breakthroughs in medical care and a greater understanding of this rare but serious condition.

Who Are The Prominent Global Companies Shaping The Penile Cancer Market Landscape?

Major companies operating in the penile cancer market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Novartis AG, F Hoffmann-La Roche Ltd, Johnson & Johnson, AbbVie Inc., GlaxoSmithKline plc, BeiGene Ltd., Iovance Biotherapeutics Inc, Lisata Therapeutics Inc, Halozyme Therapeutics Inc, Sotio Biotech, Sanofi S A, Genmab A S, Otsuka Pharmaceutical Co Ltd, Adaptimmune Therapeutics plc, Apceth Biopharma GmbH & Co KG

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/penile-cancer-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Penile Cancer Market?

North America was the largest region in the penile cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the penile cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Penile Cancer Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12143&type=smp

Browse Through More Reports Similar to the Global Penile Cancer Market 2026, By The Business Research Company

Leqembi Market Report 2026

https://www.thebusinessresearchcompany.com/report/leqembi-global-market-report

Urinary Tract Cancer Market Report 2026

https://www.thebusinessresearchcompany.com/report/urinary-tract-cancer-global-market-report

Adrenocortical Carcinoma Market Report 2026

https://www.thebusinessresearchcompany.com/report/adrenocortical-carcinoma-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795